Abstract
Understanding the impact of Mpox incidence and Mpox first dose vaccination on recent HIV testing is critical to better address both epidemics. We conducted a regression analysis of Mpox incidence and Mpox first dose vaccinations with recent HIV testing during the 2022 Mpox epidemic. We found that increased Mpox first dose vaccination was associated with a decrease in recent HIV testing in men but not women. Mpox incidence was not associated with changes in HIV testing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
